Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

January 21, 2025

Study Completion Date

January 21, 2025

Conditions
Eosinophilic Esophagitis
Interventions
DIETARY_SUPPLEMENT

Eosinophilic Esophagitis (EoE) food introduction-1st

1 serving size of food proven to induce histologic and clinical symptoms in EoE

DIETARY_SUPPLEMENT

Eosinophilic Esophagitis (E0E) food introduction-2nd

Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day

DIETARY_SUPPLEMENT

Eosinophilic Esophagitis (EoE) Food introduction-3rd dose

Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1

DRUG

Dupilumab

"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER